Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
May 03 2017 - 7:30AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer,
today announced that the Company’s first quarter 2017
financial results will be released on Tuesday, May 9, 2017.
Company management will host a conference call on Tuesday, May 9,
2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss
the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the
Investor section of the Company’s website at www.calithera.com. The
conference call can be accessed by dialing (855) 783-2599
(domestic) or (631) 485-4877 (international) and refer to
conference ID 18046993. Please log in approximately
5-10 minutes before the event to ensure a timely connection.
The archived webcast will remain available for replay on
Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally
bioavailable inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being evaluated
in Phase 1/2 clinical trials in combination with standard of care
agents. CB-1158 is a first-in-class immuno-oncology metabolic
checkpoint inhibitor targeting arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells. Arginase depletes arginine,
a nutrient that is critical for the activation, growth and survival
of the body’s cancer-fighting immune cells, known as cytotoxic
T-cells. CB-1158 is being developed in collaboration with
Incyte Corporation and is currently in a Phase 1 clinical trial.
Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024